New Data Show Treatment Of Multiple Sclerosis (MS) With AVONEX® (interferon Beta-1a) Enhances Quality Of Life

Results from a one-year prospective, observational study conducted to determine the impact of beginning treatment with AVONEX on MS patients’ overall quality of life (QoL) were announced today. The data showed that patients receiving treatment with AVONEX experienced statistically significant improvements in QoL, as measured by the EuroQol questionnaire (EQ-5D), compared to baseline.

More: continued here

Filed under: Multiple Sclerosis on April 17th, 2008